title: New approach to osteopenia in phenylketonuric patients.
abstract: OBJECTIVE
  To study bone mineralization in a group of phenylketonuric patients and to search for a possible relationship between bone mineral density, dietary control, serum minerals and nutrition intake. The response to treatment with low-dose 1.25-(OH)2 vitamin D in patients with osteopenia was evaluated.
  
  
  METHODS
  Twenty-eight phenylketonuric patients (age range: 10-33 y) on dietary treatment were investigated. Bone density at the lumbar spine (Dual Energy X-ray Absorptiometry), bone formation markers (osteocalcin and bone alkaline phosphatase), serum minerals, index of dietary control and protein, vitamin D and mineral intakes were determined.
  
  
  RESULTS
  Of the patients studied, 78.6% had good dietary compliance (462 +/- 89 micromol/L). Mean protein, vitamin D and mineral intakes met the recommended dietary allowances (RDAs). Nevertheless, 8 patients had calcium intakes lower than 1000 g/d, and a positive correlation between Z-score and calcium (r = 0.585; p = 0.002) or phosphorus intake (r = 0.546; p = 0.005) was observed. Osteopenia was detected in 14 patients (50%). Moreover, bone alkaline phosphatase in phenylketonuric patients older than 18 y of age was significantly lower than that in controls (p < 0.0001). No correlation was found between bone mineral density, age, serum minerals, bone formation markers or index of dietary control. Treatment with 0.25 microg/d calcitriol significantly increased bone density in 6 patients.
  
  
  CONCLUSIONS
  A defect in bone mineralization was detected in 50% of patients in our series. The correct amount of formula intake seems to be necessary for bone mineralization in phenylketonuric patients. Calcitriol can be a useful treatment for these patients, although more studies are needed to confirm these results. Hypercalcaemia and hypercalciuria need to be carefully monitored.
authors.affiliation: Department of Pediatrics Hospital Sant Joan de Déu-Clínic, University of Barcelona, Spain.
authors.forename: B
authors.initials: B
authors.lastname: Pérez-Dueñas
authors.forename: F J
authors.initials: FJ
authors.lastname: Cambra
authors.forename: M A
authors.initials: MA
authors.lastname: Vilaseca
authors.forename: N
authors.initials: N
authors.lastname: Lambruschini
authors.forename: J
authors.initials: J
authors.lastname: Campistol
authors.forename: J A
authors.initials: JA
authors.lastname: Camacho
mesh_terms: D000293:Adolescent; D000328:Adult; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D002117:Calcitriol / Q000627:therapeutic use*; D002120:Calcium Channel Agonists / Q000627:therapeutic use*; D002648:Child; D018753:Diet, Protein-Restricted / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008903:Minerals / Q000097:blood; D015596:Nutrition Assessment; D010349:Patient Compliance; D010661:Phenylketonurias / Q000097:blood / Q000150:complications* / Q000178:diet therapy*
chemical_list: D002120:Calcium Channel Agonists; D008903:Minerals; D002117:Calcitriol